Eli Lilly announced Monday that its gene-editing therapy VERVE-102 lowered low-density lipoprotein (LDL) cholesterol by up to 62% [1] in a Phase 1 clinical trial.
This development represents a shift toward permanent cardiovascular treatment. Unlike traditional medications that require daily pills or regular injections, this gene-editing approach aims to provide a long-term reduction in "bad" cholesterol to lower the risk of heart disease.
The therapy was developed by Verve Therapeutics, a unit Eli Lilly acquired for $1.3 billion [2]. The results from the early-phase trial indicate that the treatment effectively targets the genetic drivers of cholesterol production, a method that mimics the effects of PCSK9 inhibitors but through a one-time genomic alteration.
Following the success of the Phase 1 data, the company is preparing to launch a Phase 2 study to further evaluate the safety and efficacy of the treatment in a larger patient population [3]. The trial focused on participants with high LDL levels, seeking to prove that a single administration could maintain cholesterol suppression over time.
Medical researchers have long sought a "one-and-done" solution for hypercholesterolemia. While existing therapies are effective, patient adherence to long-term medication regimens remains a significant hurdle in preventing heart attacks and strokes. VERVE-102 seeks to eliminate this hurdle by editing the genes responsible for cholesterol regulation directly within the body [1].
Eli Lilly said the company will continue to monitor the long-term effects of the editing process to ensure there are no off-target mutations or adverse reactions as the program moves into the next stage of clinical testing [3].
“VERVE-102 lowered low-density lipoprotein (LDL) cholesterol by up to 62%”
The transition from chronic medication to a single-dose gene edit could fundamentally change the standard of care for cardiovascular health. If Phase 2 trials confirm these results, the therapy could move LDL management from a lifelong maintenance routine to a curative procedure, potentially reducing the global burden of heart disease by removing the risk of patient non-compliance.
